Blue Cross Blue Shield LA nucleic acid probe Coverage Update

Coverage Criteria and Policy Rules

Coverage by CPT and organism

Coverage status is summarized per organism and probe type with "MCC" indicating the test MEETS COVERAGE CRITERIA and "DNMCC" indicating the test DOES NOT MEET COVERAGE CRITERIA.

Organism/probe CPT mapping: Each organism has specific coverage designations for Direct Probe, Amplified Probe, and Quantification as listed in the policy table. Examples: Bartonella henselae/quintana — Amplified Probe 87471 (MCC), Quantification 87472 (DNMCC); Clostridium difficile — Amplified Probe 87493 (MCC); Cytomegalovirus — Direct 87495 (MCC), Amplified 87496 (MCC), Quantification 87497 (MCC); Herpes virus-6 — Direct 87531 (DNMCC), Amplified 87532 (DNMCC), Quantification 87533 (MCC); Orthopoxvirus — Amplified Probe 87593 (MCC).

Refer to the full table in the policy for the complete organism-to-CPT mapping and coverage designation.

Coverage criteria and recent modifications

Summary of coverage-relevant policy rules and recent material changes included in this revision.

Orthopoxvirus amplified-probe addition: CPT 87593 (orthopoxvirus, amplified probe) is included as an allowed amplified-probe code (MCC) to permit orthopoxvirus/monkeypox testing.

Added to the table to enable coverage of orthopoxvirus amplified-probe testing.

HHV-6 coverage alignment change: Direct (qualitative) HHV-6 testing (CPT 87531) has been changed to Does Not Meet Coverage Criteria (DNMCC); quantitative testing (87533) meets coverage criteria because quantitative viral load is required to distinguish active from latent infection.HHV-6 viral load >200 copies/mL (or 20 copies/μg DNA) indicates active infection per HHV-6 Foundation guidance.

Providers should order quantitative HHV-6 testing when differentiation of active versus latent infection is clinically required.

Simultaneous multiple probe types disallowed: Ordering any combination of direct probe, amplified probe, and/or quantification for the same organism in a single clinical encounter DOES NOT MEET COVERAGE CRITERIA.

Do not submit claims for multiple probe technique codes for the same organism and encounter; this is a trigger for denial.

Organisms without a specific CPT code: For microorganisms not listed with a specific CPT code, PCR testing meets coverage criteria (policy language retained for general allowance).

Use appropriate miscellaneous coding and document clinical rationale per policy.

Simultaneous ordering of more than one nucleic acid probe technique for the same organism in a single clinical encounter is excluded. Specifically, ordering any combination of direct probe, amplified probe, and/or quantification CPT codes for the same organism at the same encounter does not meet coverage criteria and may be denied. Providers should submit only the single probe technique that is clinically indicated and verify member benefits prior to ordering.

Testing for Mycoplasma genitalium has been removed from this policy and is no longer listed in the organism/probe table. Providers should order and document M. genitalium testing per policy G2157 (Diagnostic Testing of Common Sexually Transmitted Infections).

Examples of CPT-coded tests designated DNMCC in the policy table include: non-vaginal Candida probes 87480–87482, Hepatitis G probes 87525–87527, and qualitative Herpes virus‑6 direct probe 87531. The policy table lists multiple organism/probe combinations with the DNMCC designation; refer to the CPT mapping in the document for the full list.

Operational clarification: do not order multiple probe types for the same organism during a single encounter. The policy explicitly states that simultaneous ordering of any combination of direct probe, amplified probe, and/or quantification for the same organism in one encounter does not meet coverage criteria. Submit only the single probe CPT code that matches the clinical indication and ensure documentation supports the selected technique.

When Testing Is Covered

Amplification-based probes designated MCC

Amplification-based probes (amplified probe technique) are designated MCC for specific organism-targeted diagnostic testing per the policy table; follow guideline-based specimen selection and interpretation.

Amplified-probe designated MCC examples: Amplification-based (NAAT) probes are designated Meets Coverage Criteria (MCC) for multiple organisms. Examples include: Clostridium difficile — amplified probe 87493 (MCC); Cytomegalovirus — amplified probe 87496 (MCC); Enterovirus — amplified probe 87498 (MCC); Vancomycin-resistant Enterococcus (vanA/vanB) — amplified probe 87500 (MCC); Respiratory syncytial virus — amplified probe 87634 (MCC); Staphylococcus aureus (including MRSA) — amplified probes 87640/87641 (MCC).

Refer to CDC/other guidelines (e.g., CDC statements on RT-PCR for C. pneumoniae and FDA-approved PCR assays for C. difficile) for specimen selection and interpretation.

Clinical specimen guidance: Follow referenced guidance for specimen selection — for example, CDC recommends RT-PCR for acute Chlamydia pneumoniae and FDA-approved PCR assays are used for Clostridioides difficile; use appropriate specimen types per organism-specific guidance.

See CDC and other referenced guidance within the policy for specimen-specific instructions.

Procedure Codes and Coding Guidance

Organism-specific CPT codes and coverage designationCPT

87471	Bartonella henselae or quintana, Amplified Probe (MCC)
87472	Bartonella henselae or quintana, Quantification (DNMCC)
87480	Non-vaginal Candida species, Direct Probe (DNMCC)
87481	Non-vaginal Candida species, Amplified Probe (DNMCC)
87482	Non-vaginal Candida species, Quantification (DNMCC)
87485	Chlamydia pneumoniae, Direct Probe (MCC)
87486	Chlamydia pneumoniae, Amplified Probe (MCC)
87487	Chlamydia pneumoniae, Quantification (DNMCC)
87493	Clostridium difficile, Amplified Probe (MCC)
87495	Cytomegalovirus, Direct Probe (MCC)

1–10 of 30

1/3

Applicable CPT/HCPCS Procedure CodesCPT

87471	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique.
87472	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, quantification.
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique.
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.
87482	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification.
87485	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique.
87486	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique.
87487	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification.
87493	Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique.
87495	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique.

1–10 of 30

1/3

HHV-6 quantitative threshold — active infection

HHV-6 quantitative active infection threshold>200 copies/mL OR 20 copies/µg DNA (viral load threshold indicating active infection)

Clinical rationaleQuantitative PCR preferred to differentiate active versus latent HHV-6; qualitative whole-blood PCR is insufficient for this purpose.

Policy implicationOrder HHV-6 quantification (CPT 87533) when viral load is needed to determine active infection; direct probe (CPT 87531) is DNMCC.

Provider Responsibilities and Ordering Guidance

Prior Authorization

Benefit Verification

Verify member benefits and applicable Medicare/Medicaid rules before ordering nucleic acid–based testing. Coverage determinations depend on the individual's benefit plan and state or federal program rules at the time of service.

Check member-specific coverage and prior authorization requirements.
Refer to the 'Applicable State and Federal Regulations' section for Medicare/Medicaid specifications.

Billing Rule

Procedure Codes Affected

Coverage determinations apply to the listed nucleic acid–based CPT/HCPCS codes in this policy. Providers should confirm the appropriate CPT/HCPCS code for the organism tested and include required documentation in the medical record to support medical necessity.

Ordering and Laboratory Requirements

Billing Rule

ORDERING REQUIREMENTS — benefit verification and restriction on simultaneous probe orders

Before ordering nucleic acid probe tests, verify individual member benefits and applicable Medicare/Medicaid rules; note that simultaneous orders for multiple probe types for the same organism are excluded from coverage and should not be submitted.

Verify member benefits prior to ordering
Do not submit simultaneous orders for multiple probe types for the same organism

Documentation Required

ORDERING REQUIREMENTS — LDT validation and CLIA compliance

Laboratory-developed tests (LDTs) referenced in the policy may be used when appropriate; LDTs must be validated and performed in-house and are regulated as high-complexity tests under CLIA (CLIA '88).

Ensure the LDT is validated and documented in the performing laboratory
Confirm CLIA high-complexity compliance for in‑house LDTs

Frequency and Follow-up Testing

Frequency limits — general

Frequency limits specifiedNot specified in this policy.

Implication for orderingProviders should verify individual member benefits and applicable state/federal rules for any administrative limits.

Simultaneous ordersPolicy separately disallows simultaneous ordering of multiple probe types for the same organism in one encounter, which is an ordering restriction rather than a frequency limit.

Follow-up mpox testing

Follow-up testing allowedFollow-up mpox (orthopoxvirus) testing permitted as clinically indicated (e.g., clinical deterioration or to inform discharge).

Specimen types for follow-upAdditional samples may include lesion swab, throat swab (in viral transport medium), blood (EDTA), and urine as indicated.

Tests and Probe Types Not Covered

Tests and organism/probe combinations listed as DNMCC in the policy table are not covered for the indicated clinical scenarios. Examples in the table include non-vaginal Candida (87480–87482), Hepatitis G (87525–87527), and other entries explicitly marked DNMCC. Claims for CPT codes designated DNMCC for those organism/probe pairs should not be submitted for coverage under this policy.

Coverage stance changed for Herpes virus‑6: the direct (qualitative) HHV‑6 test, CPT 87531, is now designated Does Not Meet Coverage Criteria (DNMCC). The policy revision notes that quantitative testing better differentiates active versus latent HHV‑6 infection, and coverage for HHV‑6 has been aligned accordingly.

Mycoplasma genitalium testing has been removed from this policy table and should no longer be ordered under this policy. The Review/Revision History directs providers to follow policy G2157 for coverage and ordering of M. genitalium testing.

Clinical Background and Test Technology

Background: Nucleic acid hybridization technologies — including direct probe assays, amplified probe techniques such as NAATs/PCR, and quantitative PCR — detect microbial DNA or RNA with high sensitivity and specificity and are widely used across specimen types. Benefits include faster turnaround and high throughput; limitations include contamination risk, variable standardization across assays, and interpretive complexity. Quantitative PCR can measure viral load and, for some organisms (for example HHV‑6), help differentiate active from latent infection, which is why quantitative testing is preferred when that distinction is clinically necessary.

Definitions

NAATs / PCR / qPCR — definition

DefinitionNucleic acid amplification tests (NAATs) including polymerase chain reaction (PCR) and quantitative PCR (qPCR) used to detect microbial DNA or RNA.

Common termsIncludes PCR, rRT-PCR, RT-PCR, and qPCR methods referenced in policy terminology table.

Clinical roleHigh sensitivity and specificity for pathogen detection across specimen types; interpretation may require quantitative measures for certain infections.

CIDT — definition

DefinitionCulture-independent diagnostic test (CIDT): a diagnostic method that does not rely on culture to detect pathogens.

Policy contextCIDT is listed in the policy's terminology table to clarify test types referenced in coverage criteria.

OpenPayer

Identification of Microorganisms using Nucleic Acid Probes